<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017379</url>
  </required_header>
  <id_info>
    <org_study_id>E13018</org_study_id>
    <nct_id>NCT02017379</nct_id>
  </id_info>
  <brief_title>Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.</brief_title>
  <official_title>Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center, El Paso</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center, El Paso</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study comparing the effect of erythromycin or metoclopramide, 2 prokinetic drugs&#xD;
      (Drugs which are known to speed up the emptying of the stomach or in other words to move the&#xD;
      blood out of the stomach faster) given before endoscopy to patients with upper&#xD;
      Gastrointestinal bleeding compared to patients who will not receive either of these&#xD;
      medications before their endoscopy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of pre-endoscopic interventions namely erythromycin, metoclopromide&#xD;
      vs control in improving the outcomes of endoscopy in ICU patients admitted upper GI bleeding.&#xD;
&#xD;
      Specific aims:&#xD;
&#xD;
        1. Wither erythromycin, metoclopromide vs control can enable visualization of the entire&#xD;
           gastric mucosa .&#xD;
&#xD;
        2. Wither erythromycin, metoclopromide vs control can improve the quality of stomach and&#xD;
           duodenum visualization: using the scoring system by Fossard et al&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Could not recruit any subjects&#xD;
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythromycin, Metoclopromide vs Control Enabling Visualization of the Entire Gastric Mucosa .</measure>
    <time_frame>45 minutes</time_frame>
    <description>Whether erythromycin, metoclopramide versus control can enable visualization of the entire gastric mucosa .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythromycin, Metoclopromide vs Control Improving the Quality of Stomach and Duodenum Visualization</measure>
    <time_frame>45 minutes</time_frame>
    <description>Whether erythromycin, metoclopramide vs control can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Source of Bleeding</measure>
    <time_frame>45 minutes</time_frame>
    <description>Ability to identify the source of bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second-look Endoscopy</measure>
    <time_frame>48 hours</time_frame>
    <description>Need for second-look endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Units Transfused</measure>
    <time_frame>48 hours</time_frame>
    <description>Mean number of blood units transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Upper Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoclopromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no medications will be given prior to endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <arm_group_label>Erythromycin</arm_group_label>
    <other_name>Erythrocin, E-Mycin, Ery-Tab, Ilosone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopromide</intervention_name>
    <arm_group_label>Metoclopromide</arm_group_label>
    <other_name>Reglan, Maxolon, Metozolv ODT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18-80)&#xD;
&#xD;
          -  who are admitted to the ICU for hematemesis, or coffee ground emesis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients younger than 18 yrs old or older than 80 yrs&#xD;
&#xD;
          2. Patients who refuse to consent to be in our study&#xD;
&#xD;
          3. Pregnant patients&#xD;
&#xD;
          4. Prior use of prokinetics in the last 48 hours&#xD;
&#xD;
          5. History of cardiac arrhythmia&#xD;
&#xD;
          6. Allergy to erythromycin or metoclopromide&#xD;
&#xD;
          7. Patients with QT prolongation (query 7)&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed O Othman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech University Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <results_first_submitted>February 10, 2021</results_first_submitted>
  <results_first_submitted_qc>February 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2021</results_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>upper gastrointestinal bleeding</keyword>
  <keyword>melena</keyword>
  <keyword>hematemesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erythromycin</title>
          <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
        </group>
        <group group_id="P2">
          <title>Metoclopromide</title>
          <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
        </group>
        <group group_id="P3">
          <title>Control</title>
          <description>no medications will be given prior to endoscopy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
      <group_list>
        <group group_id="B1">
          <title>Erythromycin</title>
          <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
        </group>
        <group group_id="B2">
          <title>Metoclopromide</title>
          <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>no medications will be given prior to endoscopy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Erythromycin, Metoclopromide vs Control Enabling Visualization of the Entire Gastric Mucosa .</title>
        <description>Whether erythromycin, metoclopramide versus control can enable visualization of the entire gastric mucosa .</description>
        <time_frame>45 minutes</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Erythromycin, Metoclopromide vs Control Enabling Visualization of the Entire Gastric Mucosa .</title>
          <description>Whether erythromycin, metoclopramide versus control can enable visualization of the entire gastric mucosa .</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythromycin, Metoclopromide vs Control Improving the Quality of Stomach and Duodenum Visualization</title>
        <description>Whether erythromycin, metoclopramide vs control can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al</description>
        <time_frame>45 minutes</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Erythromycin, Metoclopromide vs Control Improving the Quality of Stomach and Duodenum Visualization</title>
          <description>Whether erythromycin, metoclopramide vs control can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Source of Bleeding</title>
        <description>Ability to identify the source of bleeding</description>
        <time_frame>45 minutes</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Source of Bleeding</title>
          <description>Ability to identify the source of bleeding</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Second-look Endoscopy</title>
        <description>Need for second-look endoscopy</description>
        <time_frame>48 hours</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Second-look Endoscopy</title>
          <description>Need for second-look endoscopy</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Units Transfused</title>
        <description>Mean number of blood units transfused</description>
        <time_frame>48 hours</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Units Transfused</title>
          <description>Mean number of blood units transfused</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>All cause mortality</description>
        <time_frame>30 days</time_frame>
        <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
          </group>
          <group group_id="O2">
            <title>Metoclopromide</title>
            <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>no medications will be given prior to endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>All cause mortality</description>
          <population>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</time_frame>
      <desc>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Erythromycin</title>
          <description>Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure&#xD;
Erythromycin</description>
        </group>
        <group group_id="E2">
          <title>Metoclopromide</title>
          <description>Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy&#xD;
Metoclopromide</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>no medications will be given prior to endoscopy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated and the PI has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful. No study data are available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Research Compliance Officer</name_or_title>
      <organization>Texas Tech University Health Sciences Center at El Paso</organization>
      <phone>915-215-4814</phone>
      <email>jackie.roberts@ttuhsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

